Protara Therapeutics (TARA) Depreciation & Amortization (CF) (2016 - 2026)
Protara Therapeutics' Depreciation & Amortization (CF) history spans 14 years, with the latest figure at $90000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 8.43% to $90000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $369000.0 through Mar 2026, up 11.14% year-over-year, with the annual reading at $362000.0 for FY2025, 9.04% up from the prior year.
- Depreciation & Amortization (CF) came in at $90000.0 for Q1 2026, down from $93000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $107000.0 in Q4 2023 to a low of $53000.0 in Q2 2022.
- The 5-year median for Depreciation & Amortization (CF) is $83000.0 (2024), against an average of $80764.7.
- Year-over-year, Depreciation & Amortization (CF) soared 366.67% in 2022 and then decreased 23.36% in 2024.
- Protara Therapeutics' Depreciation & Amortization (CF) stood at $75000.0 in 2022, then soared by 42.67% to $107000.0 in 2023, then fell by 23.36% to $82000.0 in 2024, then rose by 13.41% to $93000.0 in 2025, then dropped by 3.23% to $90000.0 in 2026.
- Per Business Quant, the three most recent readings for TARA's Depreciation & Amortization (CF) are $90000.0 (Q1 2026), $93000.0 (Q4 2025), and $88000.0 (Q3 2025).